SPRO — Spero Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1701108 ·
Last close
$1.22
Market Cap
$70.76M
52W High
$3.08
52W Low
$1.08
ADV30
1,783,932
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 258,000 | — | -7,538,000 | -7,203,000 | 59,021,000 | 56,129,000 | 6,087,000 |
| Dec 2025 | 39,658,000 | — | 31,405,000 | 31,520,000 | 68,919,000 | 40,265,000 | 9,898,000 |
| Sep 2025 | 3,048,000 | — | -7,329,000 | -7,382,000 | 54,170,000 | 48,616,000 | 27,676,000 |
| Jun 2025 | 11,802,000 | — | -2,361,000 | -1,700,000 | 62,119,000 | 31,194,000 | 29,291,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$7,242,000
Investing CF
—
Financing CF
$0
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.24
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-458,269,000
Inventory
—
Receivables
$44,000
ST Investments
—
EBIT TTM
$14,177,000
Pretax Income TTM
$15,496,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$46,997,000
EBITDA
—
Free Cash Flow
$28,848,500
Enterprise Value
$22,024,314
Total Cash
$50,774,000
Total Debt
$2,043,000
Shares Out
58,234,827
Trailing EPS
$0.14
Book Value
$0.76
ROE
19.2%
ROA
7.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 59,619,000 | 7,159,000 | 8,572,000 | 68,919,000 | 9,898,000 | — | -12,624,000 |
| Dec 2024 | 27,396,000 | -72,484,000 | -68,566,000 | 110,543,000 | 64,420,000 | — | -23,444,000 |
| Dec 2023 | 96,735,000 | 26,787,000 | 22,806,000 | 182,390,000 | 75,496,000 | — | -32,995,000 |
| Dec 2022 | 48,579,000 | -30,567,000 | -46,415,000 | 124,802,000 | 48,868,000 | — | -7,731,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.11
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $1.23 · call volume: 105 · put volume: 10Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PLRX | PLIANT THERAPEUTICS, INC. | $70.59M | $1.14 | — |
| IBIO | iBio, Inc. | $70.54M | $1.42 | — |
| XBIT | XBiotech Inc. | $70.43M | $2.31 | — |
| PMVP | PMV Pharmaceuticals, Inc. | $69.76M | $1.30 | — |
| OSTX | OS Therapies Inc | $72.03M | $1.55 | — |
News headlines (Yahoo Finance, 1h cache)
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript
2026-08-19 21:28 · Yahoo
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
2026-08-12 20:01 · Yahoo
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-08-05 20:05 · Yahoo
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
2026-08-04 20:01 · Yahoo
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
2026-07-27 12:00 · Yahoo
Innovent licenses IBI355 rights to Spero for up to $1.1bn
2026-07-15 10:01 · Yahoo
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
2026-07-15 09:18 · Yahoo
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
2026-07-14 10:02 · Yahoo
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
2026-07-14 10:00 · Yahoo
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
2026-07-08 06:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.